维普中文期刊产品整合服务

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

查看全文 作　　者：Xuchao [1,2]Zhang;Zhiyong [3]Liang;Shengyue [4]Wang;Shun [5]Lu;Yong [6]Song;Ying [7]Cheng;Jianming [8]Ying;Weiping [9]Liu;Yingyong [10]Hou;Yangqiu [11]Li;Yi [12]Liu;Jun [13]Hou;Xiufeng [14]Liu;Jianyong [15]Shao;Yanhong [16]Tai;Zheng [17]Wang;Li [18]Fu;Hui [7]Li;Xiaojun [19]Zhou;Hua [20]Bai;Mengzhao [21]Wang;You [22]Lu;Jinji [23]Yang;Wenzhao [23]Zhong;Qing [23]Zhou;Xuening [23]Yang;Jie [24]Wang;Cheng [25]Huang;Xiaoqing [26]Liu;Xiaoyan [27]Zhou;Shirong [28]Zhang;Hongxia [1,2]Tian;Yu [1,2]Chen;Ruibao [29]Ren;Ning [30]Liao;Chunyan [31]Wu;Zhongzheng [32]Zhu;Hongming [33]Pan;Yanhong [34]Gu;Liwei [35]Wang;Yunpeng [36]Liu;Suzhan [37]Zhang;Tianshu [38]Liu;Gong [39]Chen;Zhimin [40]Shao;Binghe [24]Xu;Qingyuan [41]Zhang;Ruihua [42]Xu;Lin [43]Shen;Yilong [1,2]Wu 高影响力作者 机构地区：[1]Guangdong Lung Cancer Institute, Medical Research Center, Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences;[2]Affiliated Guangdong Provincial People's Hospital,South China University of Technology;[3]Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences;[4]National Research Center for Translational Medicine, Shanghai, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine;[5]Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University;[6]Division of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine;[7]Department of Oncology, Jilin Cancer Hospital;[8]Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;[9]Department of Pathology, West China Hospital, Sichuan University;[10]Department of Pathology, Zhongshan Hospital, Fudan University;[11]Department of Hematology, First Affiliated Hospital, Institute of Hematology, School of Medicine, Jinan University;[12]Laboratory of Oncology, Affiliated Hospital of the Academy of Military Medical Sciences;[13]Department of Oncology, First Clinical College of South China University of Technology/Guangdong Lung Cancer Institute;[14]People's Liberation Army Cancer Center of Bayi Hospital Affiliated to Nanjing University of Chinese Medicine;[15]Department of Pathology, Sun Yat-sen University Cancer Center;[16]Department of Pathology,Affiliated Hospital of the Academy of Military Medical Sciences;[17]Department of Pathology, Beijing Hospital;[18]Department of Breast Cancer Pathology and Research Laboratory of Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer;[19]Department of Pathology, Jinling Hospital Nanjing University School of Medicine;[20]State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;[21]Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences;[22]Department of Oncology,West China Hospital, Sichuan University;[23]Guangdong Lung Cancer Institute, Guangdong Provincical Prople's Hospital, Guangdong Academy of Medical Sciences;[24]Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;[25]Department of Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital;[26]Department of Oncology, Affiliated Hospital of the Academy of Military Medical Sciences;[27]Department of Pathology, Shanghai Cancer Center, Fudan University;[28]Center for Translational Medicine, Hangzhou First People's Hospital, Nanjing Medical University;[29]State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, ShanghaiJiao Tong University School of Medicine;[30]Department of Breast Cancer, Cancer Center,Guangdong Provincial People's Hospital;[31]Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine;[32]Department of Oncology, No. 113 Hospital of People's Liberation Army;[33]Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University;[34]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital;[35]Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine;[36]Department of Medical Oncology, The First Hospital of China Medical University;[37]Department of Oncology, Second Affiliated Hospital, School of Medicine, Zhejiang University;[38]Department of Oncology, Zhongshan Hospital, Fudan University;[39]Department of Colorectal, Sun Yat-sen University Cancer Center;[40]Department of Breast Surgery, Shanghai Cancer Center, Fudan University;[41]Department of Internal Medicine, The Third Affiliated Hospital of Harbin Medical University;[42]Department of Medical Oncology, Sun Yat-Sen University Cancer Center;[43]Department of Gastrointestinal Oncology,Peking University Cancer Hospital and Institute高影响力机构 出　　处：《Cancer Biology & Medicine》索引2019年第16卷第1期,共16页高影响力期刊 基　　金：supported by grants from Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (Grant No. 2017B030314120);General Research Project of Guangzhou Science and Technology Bureau (Grant No. 201607010391);National Key Research and Development Program of China (Grant No. 2016YFC1303800);Guangdong Provincial Applied S&T R&D Program (Grant No. 2016B020237006) 摘　　要：Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules simultaneously.Therefore, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology(CSCO) and the China Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation. 关 键 词：Next-generation SEQUENCING TECHNOLOGY CANCER consensus
相关文献

参考文献(74)

引证文献(17)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费